This Summit is focused on Cancer Immunotherapy, the most promising new cancer treatment approach since the development of the first chemotherapies. This summit brings together leading industry professionals in order ...
http://www.immuno-oncologysummit.com/ The Immuno-Oncology Summit will return to Boston again this August 28-September 1 with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing ...
PRECISION: LUNG CANCER JULY 25-26 2017 BOSTON USA A GLOBAL PHARMA R&D SUMMIT http://precisionlungcancer.com/
On June 13, Immunomic Therapeutics Inc. (ITI) participated in the “Making a Name in Cancer Immunotherapy” webcast, hosted by Nature.com. Other participating companies included Isoplexis, Merus, and Actinium Pharmaceuticals, Inc. ...
Immunomic Therapeutics Inc. is looking forward to attending the annual BIO Convention in San Diego, California next week. The International BIO Convention brings together nearly 16,000 innovators and researchers from ...
Science and health innovation do not exist in a vacuum. The cultural, social and political climate can indeed have a profound effect on funding priorities, public acceptance of new technologies ...
June 12, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc., will participate in a BioPharma Dealmakers webcast, sponsored in ...
Sunday, June 4, 2017, is National Cancer Survivors Day and we are celebrating those who have defeated cancer and supporting patients who are currently fighting the disease. Over the past ...
Bill Hearl and Greg Simon to Examine Lessons from the Cancer Moonshot Initiative May 23, 2017 08:00 AM Eastern Daylight Time WASHINGTON--(BUSINESS WIRE)-- Tomorrow, IVY and Immunomic Therapeutics, Inc. (ITI) ...
May 22, 2017 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. (ITI) Senior Vice President of Research and Development Teri Heiland, Ph.D., will present on DNA vaccines ...
Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV) Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics for use in combination with Immunomic’s investigational ...
Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™ May 18, 2017 Eastern Standard Time ROCKVILLE, Md. & SAN FRANCISCO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, ...